MATCHPOINT THERAPEUTICS Trademark

Trademark Overview

On Tuesday, January 11, 2022, a trademark application was filed for MATCHPOINT THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the MATCHPOINT THERAPEUTICS trademark a serial number of 97212521. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Friday, February 16, 2024. This trademark is owned by EoCys Inc.. The MATCHPOINT THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of oncologic, autoimmune, inflammatory, metabolic, rheumatic, dermatological, endocrine, ophthalmologic, neurologic, cardiovascular, gastrointestinal, and viral disease
matchpoint therapeutics

General Information

Serial Number97212521
Word MarkMATCHPOINT THERAPEUTICS
Filing DateTuesday, January 11, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateFriday, February 16, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 11, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the prevention and treatment of oncologic, autoimmune, inflammatory, metabolic, rheumatic, dermatological, endocrine, ophthalmologic, neurologic, cardiovascular, gastrointestinal, and viral disease
Pseudo MarkMATCH POINT THERAPEUTICS
Disclaimer with Predetermined Text"THERAPEUTICS"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 18, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEoCys Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
Party NameEoCys Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Saturday, February 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, February 17, 2024CORRECTED NOA E-MAILED
Friday, February 16, 2024SOU EXTENSION 1 GRANTED
Wednesday, January 24, 2024SOU EXTENSION 1 FILED
Friday, February 16, 2024DIVISIONAL PROCESSING COMPLETE
Wednesday, January 24, 2024DIVISIONAL REQUEST RECEIVED
Wednesday, February 7, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, January 24, 2024TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, January 24, 2024SOU TEAS EXTENSION RECEIVED
Friday, January 5, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, January 5, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 5, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, January 5, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, September 5, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 11, 2023PUBLISHED FOR OPPOSITION
Wednesday, June 21, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, June 8, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 5, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 4, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 4, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 4, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, November 4, 2022NON-FINAL ACTION E-MAILED
Friday, November 4, 2022NON-FINAL ACTION WRITTEN
Wednesday, October 19, 2022ASSIGNED TO EXAMINER
Tuesday, January 18, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 14, 2022NEW APPLICATION ENTERED

Related Keywords

therapeutics matchpoint neurologic ophthalmologic endocrine cardiovascular gastrointestinal disease viral dermatological rheumatic treatment